Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Eric Wu

Concepts (464)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Health Care Costs
31
2022
428
4.010
 Why?
Hyperkalemia
4
2021
36
2.440
 Why?
Everolimus
10
2016
112
2.260
 Why?
Health Resources
10
2026
133
2.240
 Why?
Cost of Illness
13
2022
327
1.950
 Why?
Health Services
11
2016
113
1.450
 Why?
Breast Neoplasms
16
2018
2420
1.430
 Why?
Antineoplastic Agents
20
2018
2231
1.390
 Why?
Citalopram
6
2012
33
1.180
 Why?
Receptors, Antigen, T-Cell
4
2021
679
1.110
 Why?
Receptors, Estrogen
3
2015
406
1.100
 Why?
Health Expenditures
9
2020
199
1.100
 Why?
Medication Adherence
4
2015
540
1.030
 Why?
Psoriasis
5
2018
115
0.980
 Why?
Immunotherapy, Adoptive
2
2020
356
0.940
 Why?
Insurance Claim Review
18
2017
86
0.940
 Why?
Practice Patterns, Physicians'
6
2018
1379
0.930
 Why?
United States
52
2022
16313
0.910
 Why?
Hepatitis C, Chronic
3
2019
154
0.900
 Why?
Pyrimidines
7
2014
532
0.870
 Why?
Renal Insufficiency, Chronic
3
2021
673
0.850
 Why?
Drug Substitution
3
2019
64
0.850
 Why?
Piperazines
6
2014
375
0.850
 Why?
Middle Aged
76
2026
36821
0.840
 Why?
Biosimilar Pharmaceuticals
2
2022
28
0.840
 Why?
Receptors, Progesterone
2
2015
244
0.810
 Why?
Attention Deficit Disorder with Hyperactivity
4
2012
434
0.780
 Why?
Aged
57
2026
26516
0.760
 Why?
Models, Economic
2
2020
64
0.760
 Why?
Retrospective Studies
46
2026
17561
0.760
 Why?
Comparative Effectiveness Research
3
2012
170
0.750
 Why?
Benzamides
6
2014
227
0.740
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
2014
128
0.730
 Why?
Antifungal Agents
4
2017
153
0.720
 Why?
Humans
123
2026
147306
0.710
 Why?
Cost-Benefit Analysis
15
2022
654
0.700
 Why?
Imatinib Mesylate
7
2014
77
0.700
 Why?
Female
93
2026
80081
0.690
 Why?
Central Nervous System Stimulants
3
2012
187
0.680
 Why?
Lymphoma, Large B-Cell, Diffuse
2
2021
196
0.660
 Why?
Hospital Costs
3
2020
130
0.650
 Why?
Gout
2
2012
34
0.650
 Why?
Rheumatology
1
2022
136
0.640
 Why?
Acidosis
1
2021
107
0.630
 Why?
Adult
58
2026
41406
0.630
 Why?
Male
79
2026
73954
0.620
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
299
0.620
 Why?
Proportional Hazards Models
14
2017
1344
0.610
 Why?
Hypoglycemic Agents
4
2015
1415
0.610
 Why?
Kaplan-Meier Estimate
12
2018
975
0.610
 Why?
Nocturia
1
2019
8
0.610
 Why?
Antibodies, Monoclonal
7
2018
1514
0.590
 Why?
Antineoplastic Combined Chemotherapy Protocols
11
2018
2001
0.590
 Why?
Databases, Factual
13
2021
1504
0.580
 Why?
Prevalence
11
2021
2889
0.570
 Why?
Postmenopause
7
2018
394
0.570
 Why?
Comorbidity
12
2014
1672
0.550
 Why?
Hospitalization
15
2021
2496
0.540
 Why?
Medicare
10
2022
915
0.530
 Why?
Nutrition Surveys
1
2019
279
0.530
 Why?
Proline
2
2015
82
0.530
 Why?
Candida
2
2017
46
0.520
 Why?
Leukemia, Myeloid, Chronic-Phase
2
2014
3
0.520
 Why?
Fluconazole
1
2017
24
0.510
 Why?
Candidemia
1
2017
16
0.500
 Why?
Protein Kinase Inhibitors
5
2014
984
0.500
 Why?
Cardiologists
1
2017
45
0.500
 Why?
Myocardial Perfusion Imaging
1
2017
50
0.500
 Why?
Fees, Pharmaceutical
3
2016
8
0.490
 Why?
Tomography, Emission-Computed, Single-Photon
1
2017
104
0.490
 Why?
Oligopeptides
2
2015
267
0.480
 Why?
Aftercare
2
2021
225
0.470
 Why?
Thrombolytic Therapy
1
2017
165
0.470
 Why?
Diabetes Mellitus, Type 2
5
2015
2627
0.470
 Why?
Cystitis, Interstitial
2
2006
20
0.470
 Why?
Biological Therapy
1
2016
28
0.470
 Why?
Antidepressive Agents, Second-Generation
3
2011
46
0.460
 Why?
Antirheumatic Agents
2
2016
308
0.460
 Why?
Antiviral Agents
3
2019
776
0.460
 Why?
Neoplasm Recurrence, Local
4
2026
1166
0.450
 Why?
Drug Eruptions
1
2015
28
0.440
 Why?
Tissue Plasminogen Activator
1
2017
248
0.440
 Why?
Propylamines
2
2012
11
0.430
 Why?
Costs and Cost Analysis
10
2019
221
0.430
 Why?
Physicians, Primary Care
1
2017
210
0.420
 Why?
Methylphenidate
2
2012
49
0.420
 Why?
Fibrinolytic Agents
1
2017
303
0.420
 Why?
Gastrointestinal Stromal Tumors
1
2014
41
0.420
 Why?
Diphosphonates
2
2012
68
0.410
 Why?
Delivery of Health Care
2
2019
951
0.410
 Why?
Health Care Rationing
2
2016
56
0.410
 Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2008
347
0.410
 Why?
Insulin
3
2015
2526
0.410
 Why?
Patient Acceptance of Health Care
8
2026
895
0.400
 Why?
Anemia
1
2015
192
0.390
 Why?
Brain Ischemia
1
2017
362
0.390
 Why?
Imidazoles
2
2012
247
0.390
 Why?
Treatment Outcome
24
2021
11947
0.390
 Why?
Hypertension
5
2018
1280
0.380
 Why?
Neoplasm Metastasis
8
2018
695
0.380
 Why?
Insurance, Health
5
2011
321
0.380
 Why?
Dextroamphetamine
1
2012
4
0.370
 Why?
Guanfacine
1
2012
5
0.360
 Why?
Antineoplastic Agents, Hormonal
4
2016
196
0.360
 Why?
Aged, 80 and over
14
2020
8432
0.360
 Why?
Pharmacoepidemiology
1
2012
24
0.360
 Why?
Liver Neoplasms
2
2015
787
0.350
 Why?
Attention Deficit and Disruptive Behavior Disorders
1
2012
56
0.350
 Why?
Patient Compliance
3
2011
591
0.340
 Why?
Schizophrenia
2
2006
489
0.340
 Why?
Medicaid
3
2012
475
0.340
 Why?
Pulmonary Embolism
1
2014
246
0.340
 Why?
Drug Delivery Systems
1
2015
381
0.340
 Why?
Drug Costs
6
2015
117
0.330
 Why?
Fumarates
1
2011
10
0.330
 Why?
Disease-Free Survival
7
2019
779
0.330
 Why?
Antibodies, Monoclonal, Humanized
9
2018
1005
0.330
 Why?
Drugs, Generic
1
2011
28
0.330
 Why?
Bone Diseases
1
2011
61
0.320
 Why?
Referral and Consultation
1
2017
886
0.320
 Why?
Amides
1
2011
101
0.310
 Why?
Angiotensin Receptor Antagonists
1
2011
116
0.310
 Why?
Triazoles
4
2016
191
0.310
 Why?
Stroke
2
2017
1287
0.300
 Why?
Drug Monitoring
4
2016
402
0.300
 Why?
Angiotensin-Converting Enzyme Inhibitors
1
2011
230
0.300
 Why?
Venous Thromboembolism
1
2014
330
0.300
 Why?
Arthritis, Rheumatoid
2
2016
1183
0.290
 Why?
Tumor Necrosis Factor-alpha
5
2022
1225
0.290
 Why?
Potassium
2
2021
152
0.290
 Why?
Crohn Disease
5
2012
262
0.290
 Why?
Heart Failure
3
2020
2334
0.290
 Why?
Sick Leave
2
2007
16
0.290
 Why?
Hyperuricemia
1
2009
47
0.290
 Why?
Diabetes Mellitus
1
2018
1107
0.290
 Why?
Myelodysplastic Syndromes
2
2021
170
0.280
 Why?
Anticoagulants
1
2014
751
0.270
 Why?
Oligonucleotides
2
2019
154
0.270
 Why?
Absenteeism
2
2005
52
0.270
 Why?
Uric Acid
1
2009
168
0.270
 Why?
Quality of Life
9
2021
3246
0.260
 Why?
Risk Factors
12
2017
11017
0.260
 Why?
Insurance Claim Reporting
2
2007
26
0.260
 Why?
Multiple Myeloma
1
2011
310
0.260
 Why?
Randomized Controlled Trials as Topic
3
2012
1777
0.250
 Why?
Physicians
1
2015
961
0.250
 Why?
Head and Neck Neoplasms
1
2012
569
0.250
 Why?
Hypoglycemia
1
2012
489
0.240
 Why?
Health Status Indicators
1
2007
168
0.240
 Why?
Leukemia, Myeloid, Acute
2
2026
700
0.240
 Why?
Young Adult
14
2026
14437
0.240
 Why?
Drug Therapy, Combination
6
2019
1046
0.240
 Why?
Pentosan Sulfuric Polyester
1
2006
2
0.230
 Why?
Economics, Pharmaceutical
1
2006
10
0.230
 Why?
Drug Resistance, Fungal
2
2017
8
0.230
 Why?
Treatment Failure
3
2017
360
0.230
 Why?
fms-Like Tyrosine Kinase 3
1
2026
51
0.230
 Why?
Endometriosis
2
2017
58
0.220
 Why?
Adolescent
22
2026
22826
0.220
 Why?
Urinary Incontinence
1
2005
65
0.210
 Why?
Prostatic Neoplasms
2
2012
986
0.210
 Why?
Diagnostic Errors
1
2006
182
0.210
 Why?
Nitriles
3
2016
211
0.210
 Why?
Immunoglobulin G
1
2008
901
0.210
 Why?
Recurrence
3
2020
1151
0.200
 Why?
Electronic Health Records
2
2021
1214
0.190
 Why?
Protein-Tyrosine Kinases
4
2014
432
0.190
 Why?
Emergency Service, Hospital
4
2021
2416
0.190
 Why?
Antihypertensive Agents
3
2012
522
0.190
 Why?
Molecular Targeted Therapy
3
2015
444
0.190
 Why?
Psychotic Disorders
1
2005
199
0.180
 Why?
Genetic Therapy
2
2021
317
0.180
 Why?
Thiophenes
2
2014
117
0.180
 Why?
Infliximab
1
2022
111
0.170
 Why?
Delayed-Action Preparations
3
2017
191
0.170
 Why?
Population Surveillance
1
2005
486
0.170
 Why?
Anti-Inflammatory Agents
3
2011
481
0.170
 Why?
Giant Cell Tumor of Tendon Sheath
1
2021
9
0.170
 Why?
Bone Density Conservation Agents
2
2012
82
0.170
 Why?
Gout Suppressants
2
2012
19
0.170
 Why?
Gastritis
1
2022
117
0.160
 Why?
Enteritis
1
2022
105
0.160
 Why?
Carcinoma, Non-Small-Cell Lung
3
2015
1195
0.160
 Why?
Polymerase Chain Reaction
2
2014
1046
0.160
 Why?
Biological Products
2
2016
258
0.160
 Why?
Severity of Illness Index
6
2018
2974
0.160
 Why?
Hemophilia B
1
2021
65
0.160
 Why?
Atomoxetine Hydrochloride
2
2012
8
0.160
 Why?
Antimetabolites, Antineoplastic
1
2021
108
0.160
 Why?
Bronchodilator Agents
2
2011
187
0.160
 Why?
Adenocarcinoma
1
2007
928
0.150
 Why?
Time Factors
5
2017
7173
0.150
 Why?
Voriconazole
2
2016
21
0.150
 Why?
Eosinophilia
1
2022
224
0.150
 Why?
Immunologic Factors
1
2022
261
0.150
 Why?
National Health Programs
1
2019
23
0.150
 Why?
Regression Analysis
4
2012
1003
0.150
 Why?
Technology Assessment, Biomedical
1
2019
45
0.150
 Why?
Pulmonary Disease, Chronic Obstructive
3
2011
928
0.150
 Why?
Hemophilia A
1
2021
149
0.150
 Why?
Aromatase Inhibitors
2
2018
81
0.150
 Why?
Muscular Atrophy, Spinal
1
2019
30
0.150
 Why?
Atrial Fibrillation
1
2005
560
0.150
 Why?
Survival of Motor Neuron 1 Protein
1
2019
11
0.150
 Why?
Patient Readmission
2
2017
777
0.150
 Why?
Health Services Research
1
2021
392
0.140
 Why?
Spinal Muscular Atrophies of Childhood
1
2019
20
0.140
 Why?
Survival Analysis
4
2018
1386
0.140
 Why?
Multivariate Analysis
5
2015
1550
0.140
 Why?
Microbial Sensitivity Tests
2
2017
367
0.140
 Why?
Urologic Neoplasms
1
2018
31
0.140
 Why?
China
2
2021
278
0.140
 Why?
Idiopathic Pulmonary Fibrosis
2
2015
696
0.140
 Why?
Aging
1
2009
1992
0.130
 Why?
Europe
3
2019
426
0.130
 Why?
Vital Capacity
2
2015
293
0.130
 Why?
Polystyrenes
1
2018
38
0.130
 Why?
Managed Care Programs
2
2010
140
0.130
 Why?
Antidepressive Agents
2
2011
245
0.130
 Why?
Chronic Disease
4
2014
1845
0.130
 Why?
Time-to-Treatment
2
2017
258
0.130
 Why?
4-Aminopyridine
1
2017
30
0.130
 Why?
Retreatment
1
2017
80
0.130
 Why?
Overweight
1
2022
617
0.130
 Why?
Thiazoles
2
2014
142
0.120
 Why?
Aspergillosis
1
2016
24
0.120
 Why?
Drug Administration Schedule
4
2013
789
0.120
 Why?
Chemotherapy, Adjuvant
2
2016
429
0.120
 Why?
Patient Preference
1
2019
225
0.120
 Why?
Abiraterone Acetate
1
2016
15
0.120
 Why?
Administration, Intravenous
1
2017
172
0.120
 Why?
Consumer Behavior
1
2017
70
0.120
 Why?
Hysterectomy
1
2017
138
0.120
 Why?
Administrative Claims, Healthcare
1
2016
28
0.120
 Why?
Mental Disorders
1
2005
1188
0.120
 Why?
Prostatic Neoplasms, Castration-Resistant
1
2016
54
0.120
 Why?
Capecitabine
1
2016
56
0.120
 Why?
Disability Evaluation
1
2017
312
0.110
 Why?
Trastuzumab
1
2016
119
0.110
 Why?
Prednisone
1
2016
230
0.110
 Why?
Clinical Protocols
1
2017
284
0.110
 Why?
Androstadienes
1
2015
77
0.110
 Why?
Ki-1 Antigen
1
2015
7
0.110
 Why?
Patient Admission
1
2017
220
0.110
 Why?
International Classification of Diseases
1
2016
151
0.110
 Why?
Waiting Lists
1
2017
268
0.110
 Why?
Logistic Models
2
2014
2142
0.110
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2015
23
0.110
 Why?
Patient Discharge
1
2021
1002
0.110
 Why?
Ribavirin
1
2015
81
0.110
 Why?
Drug Interactions
1
2016
405
0.110
 Why?
Ambulatory Care
3
2015
625
0.110
 Why?
Neoplasm Staging
2
2015
1492
0.100
 Why?
California
2
2006
477
0.100
 Why?
Carboplatin
1
2014
168
0.100
 Why?
Heparin, Low-Molecular-Weight
1
2014
37
0.100
 Why?
International Normalized Ratio
1
2014
56
0.100
 Why?
Amphotericin B
1
2014
36
0.100
 Why?
Cytogenetic Analysis
1
2013
34
0.100
 Why?
Recombinant Proteins
1
2017
1371
0.100
 Why?
Insurance, Health, Reimbursement
1
2014
98
0.100
 Why?
Japan
3
2021
149
0.100
 Why?
Models, Theoretical
1
2017
563
0.100
 Why?
Cross-Sectional Studies
3
2019
6011
0.100
 Why?
Follow-Up Studies
5
2015
5478
0.100
 Why?
Drug Prescriptions
1
2015
293
0.100
 Why?
Constipation
1
2014
98
0.100
 Why?
Paclitaxel
1
2014
261
0.100
 Why?
Morpholines
1
2014
130
0.100
 Why?
ErbB Receptors
2
2016
638
0.100
 Why?
Immunoconjugates
1
2015
138
0.100
 Why?
Receptor Protein-Tyrosine Kinases
1
2015
231
0.100
 Why?
Mycoses
1
2014
88
0.100
 Why?
Budgets
1
2012
14
0.090
 Why?
Recovery of Function
1
2017
724
0.090
 Why?
Hodgkin Disease
1
2015
173
0.090
 Why?
Drug Combinations
2
2011
399
0.090
 Why?
Allopurinol
1
2012
70
0.090
 Why?
Adalimumab
5
2011
54
0.090
 Why?
Warfarin
1
2014
179
0.090
 Why?
Cohort Studies
5
2016
6099
0.090
 Why?
Lisdexamfetamine Dimesylate
1
2012
8
0.090
 Why?
Laparoscopy
1
2017
486
0.090
 Why?
New Zealand
1
2012
56
0.090
 Why?
Immunocompromised Host
1
2014
202
0.090
 Why?
Pyridines
1
2016
610
0.090
 Why?
Ethanolamines
1
2012
14
0.090
 Why?
Gastrointestinal Diseases
1
2014
222
0.090
 Why?
Databases as Topic
2
2009
71
0.090
 Why?
Health Status
2
2008
839
0.090
 Why?
Benzopyrans
1
2012
31
0.090
 Why?
Genetic Testing
1
2015
493
0.090
 Why?
Clinical Trials as Topic
2
2019
1072
0.090
 Why?
Estradiol
1
2015
515
0.090
 Why?
Triple Negative Breast Neoplasms
1
2014
220
0.090
 Why?
Florida
1
2012
118
0.090
 Why?
Sulfonylurea Compounds
1
2012
51
0.090
 Why?
Multiple Sclerosis
1
2017
491
0.090
 Why?
Rivaroxaban
1
2014
271
0.090
 Why?
Pleural Effusion
1
2012
60
0.090
 Why?
Neurotransmitter Uptake Inhibitors
1
2011
3
0.080
 Why?
North America
1
2012
307
0.080
 Why?
Fractures, Spontaneous
1
2011
15
0.080
 Why?
Cyclohexanols
1
2011
9
0.080
 Why?
Surveys and Questionnaires
4
2021
6164
0.080
 Why?
Australia
1
2012
299
0.080
 Why?
Lung Neoplasms
2
2015
2679
0.080
 Why?
Hypercalcemia
1
2011
23
0.080
 Why?
Nebulizers and Vaporizers
1
2011
63
0.080
 Why?
Spinal Cord Compression
1
2011
24
0.080
 Why?
Drug Resistance, Neoplasm
2
2026
889
0.080
 Why?
Child
6
2020
22980
0.080
 Why?
Cost Sharing
1
2011
23
0.080
 Why?
Sirolimus
1
2012
283
0.080
 Why?
Efficiency
2
2011
103
0.080
 Why?
Adamantane
1
2011
18
0.080
 Why?
Models, Statistical
2
2012
677
0.080
 Why?
Bone Diseases, Metabolic
1
2011
59
0.080
 Why?
Case-Control Studies
3
2014
3660
0.080
 Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2011
46
0.080
 Why?
Communication
1
2017
989
0.080
 Why?
Health Benefit Plans, Employee
2
2009
25
0.080
 Why?
Norepinephrine
1
2011
201
0.080
 Why?
Bone Neoplasms
1
2012
272
0.080
 Why?
Pyrazines
1
2011
94
0.080
 Why?
Pyrrolidines
1
2011
126
0.080
 Why?
Angiogenesis Inhibitors
1
2011
239
0.070
 Why?
Linear Models
1
2012
852
0.070
 Why?
Gastrointestinal Agents
1
2009
65
0.070
 Why?
Administration, Oral
1
2012
874
0.070
 Why?
Etanercept
1
2008
60
0.070
 Why?
Drug Utilization
1
2010
171
0.070
 Why?
Serotonin
1
2011
300
0.070
 Why?
Blood Chemical Analysis
1
2009
109
0.070
 Why?
Obesity
1
2022
3149
0.070
 Why?
Receptors, Tumor Necrosis Factor
1
2008
163
0.070
 Why?
Age Distribution
3
2015
406
0.070
 Why?
Depressive Disorder
1
2011
379
0.070
 Why?
Amphetamines
1
2007
6
0.070
 Why?
Adrenergic Uptake Inhibitors
1
2007
14
0.070
 Why?
Insurance, Pharmaceutical Services
1
2007
24
0.070
 Why?
Employment
2
2007
184
0.060
 Why?
Digestive System Surgical Procedures
1
2008
112
0.060
 Why?
Medical Audit
1
2007
77
0.060
 Why?
Quality-Adjusted Life Years
2
2022
126
0.060
 Why?
Age Factors
3
2015
3372
0.060
 Why?
Veterans Disability Claims
1
2006
4
0.060
 Why?
Disease Progression
4
2015
2892
0.060
 Why?
Algorithms
1
2014
1868
0.060
 Why?
Laboratories
1
2007
111
0.060
 Why?
Private Sector
1
2006
50
0.060
 Why?
Employer Health Costs
1
2005
4
0.060
 Why?
Coronary Disease
1
2008
382
0.060
 Why?
Ischemic Attack, Transient
1
2006
71
0.060
 Why?
Metabolic Diseases
1
2007
114
0.060
 Why?
Mexico
1
2026
233
0.060
 Why?
Hallucinations
1
2005
33
0.060
 Why?
Atrial Flutter
1
2005
47
0.050
 Why?
Asthma
2
2007
1805
0.050
 Why?
Double-Blind Method
4
2011
2080
0.050
 Why?
Area Under Curve
1
2005
334
0.050
 Why?
Administration, Inhalation
3
2011
572
0.050
 Why?
Diagnostic and Statistical Manual of Mental Disorders
1
2005
232
0.050
 Why?
Adrenal Cortex Hormones
1
2007
487
0.050
 Why?
Dasatinib
2
2014
58
0.050
 Why?
Metabolic Syndrome
1
2007
365
0.050
 Why?
Anti-Asthmatic Agents
1
2006
264
0.050
 Why?
Data Collection
1
2006
652
0.050
 Why?
Body Weight
1
2007
976
0.050
 Why?
Psychiatric Status Rating Scales
1
2005
537
0.050
 Why?
Colorectal Neoplasms
1
2011
877
0.050
 Why?
Lung
1
2015
4141
0.050
 Why?
Bevacizumab
2
2014
168
0.050
 Why?
Health Policy
1
2005
405
0.040
 Why?
Diagnosis, Differential
1
2006
1518
0.040
 Why?
Interviews as Topic
1
2005
932
0.040
 Why?
Dose-Response Relationship, Drug
3
2011
2030
0.040
 Why?
Information Storage and Retrieval
1
2021
123
0.040
 Why?
Veterans
1
2013
1675
0.040
 Why?
Glucagon-Like Peptides
1
2022
76
0.040
 Why?
Mental Health Services
1
2005
478
0.040
 Why?
Hematopoietic Stem Cell Transplantation
1
2026
703
0.040
 Why?
Infant
4
2019
10195
0.040
 Why?
Asia
1
2019
70
0.040
 Why?
Azacitidine
1
2021
168
0.040
 Why?
Remission Induction
2
2011
310
0.040
 Why?
France
1
2019
40
0.040
 Why?
Spain
1
2019
51
0.040
 Why?
Incidence
1
2006
2954
0.040
 Why?
Reproducibility of Results
1
2007
3448
0.040
 Why?
Italy
1
2019
118
0.040
 Why?
Germany
1
2019
140
0.040
 Why?
Cyclin-Dependent Kinase 4
1
2018
53
0.030
 Why?
Neutropenia
1
2018
154
0.030
 Why?
Sex Factors
2
2015
2136
0.030
 Why?
Potassium Channel Blockers
1
2017
47
0.030
 Why?
Disease Management
2
2015
654
0.030
 Why?
Models, Econometric
1
2016
35
0.030
 Why?
Bayes Theorem
1
2019
428
0.030
 Why?
Veterans Health
1
2018
191
0.030
 Why?
Itraconazole
1
2016
8
0.030
 Why?
B-Lymphocytes
1
2020
878
0.030
 Why?
Antineoplastic Protocols
1
2014
6
0.030
 Why?
Utilization Review
1
2014
39
0.030
 Why?
Early Diagnosis
1
2015
254
0.030
 Why?
Cardiovascular Diseases
1
2007
2218
0.030
 Why?
Forced Expiratory Volume
1
2015
451
0.030
 Why?
Aspergillus
1
2014
18
0.030
 Why?
Gene Rearrangement
1
2015
156
0.030
 Why?
Hypothyroidism
1
2014
68
0.030
 Why?
Genes, abl
1
2013
4
0.030
 Why?
Cryptococcus
1
2014
16
0.030
 Why?
Medication Therapy Management
1
2014
73
0.030
 Why?
Anemia, Iron-Deficiency
1
2014
62
0.020
 Why?
Peripheral Vascular Diseases
1
2014
105
0.020
 Why?
Socioeconomic Factors
1
2018
1342
0.020
 Why?
Mood Disorders
1
2014
145
0.020
 Why?
Drug Utilization Review
1
2013
61
0.020
 Why?
Myocardium
1
2018
949
0.020
 Why?
Acute Disease
1
2015
1049
0.020
 Why?
Propensity Score
1
2014
379
0.020
 Why?
Atenolol
1
2012
8
0.020
 Why?
Nebivolol
1
2012
9
0.020
 Why?
Biopsy
1
2015
1093
0.020
 Why?
Metoprolol
1
2012
26
0.020
 Why?
Propanolamines
1
2012
40
0.020
 Why?
Carbazoles
1
2012
53
0.020
 Why?
Risk
1
2014
927
0.020
 Why?
Matched-Pair Analysis
1
2011
37
0.020
 Why?
Decision Making
1
2019
994
0.020
 Why?
Duloxetine Hydrochloride
1
2011
10
0.020
 Why?
Venlafaxine Hydrochloride
1
2011
12
0.020
 Why?
Nervous System Diseases
1
2014
288
0.020
 Why?
Cetuximab
1
2011
111
0.020
 Why?
Sitagliptin Phosphate
1
2011
31
0.020
 Why?
Tablets
1
2010
41
0.020
 Why?
State Medicine
1
2009
26
0.020
 Why?
Epidemiologic Methods
1
2009
91
0.020
 Why?
Length of Stay
1
2015
1371
0.020
 Why?
Critical Care
1
2015
705
0.020
 Why?
Injections, Subcutaneous
1
2009
170
0.020
 Why?
Blood Glucose
2
2011
2359
0.020
 Why?
Maximum Tolerated Dose
1
2009
217
0.020
 Why?
Insurance Coverage
1
2010
248
0.020
 Why?
United Kingdom
1
2009
391
0.020
 Why?
Odds Ratio
1
2011
1084
0.020
 Why?
Probability
1
2009
309
0.020
 Why?
Statistics, Nonparametric
1
2009
430
0.020
 Why?
Confidence Intervals
1
2008
330
0.020
 Why?
Canada
1
2009
435
0.020
 Why?
Reference Values
1
2009
800
0.020
 Why?
Sex Distribution
1
2008
390
0.020
 Why?
Longitudinal Studies
1
2014
3029
0.020
 Why?
Prognosis
1
2015
4384
0.020
 Why?
Models, Biological
1
2014
1772
0.010
 Why?
Analysis of Variance
1
2009
1302
0.010
 Why?
RNA, Messenger
1
2013
2812
0.010
 Why?
Tomography, X-Ray Computed
1
2015
2791
0.010
 Why?
Health Status Disparities
1
2008
324
0.010
 Why?
Child, Preschool
2
2007
12017
0.010
 Why?
Emergency Medical Services
1
2007
691
0.010
 Why?
Risk Assessment
1
2009
3784
0.010
 Why?
Body Mass Index
1
2007
2470
0.010
 Why?
Infant, Newborn
1
2006
6543
0.010
 Why?
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (464) concept(s)
_
Co-Authors Expand Description
See all (2) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)